Gilead will integrate Interius, the first biotech to push an in vivo CAR-T therapy into the clinic, into its cell therapy ...

SANTA MONICA, CA & PHILADELPHIA, PA, USA I August 21, 2025 I Kite, a Gilead Company (Nasdaq: GILD), today announced that it has entered into a definitive ...

Michael J. Sofia, the inventor of the Hepatitis C cure, has joined the Pennsylvania Biotechnology Center in Doylestown, ...

Gilead stock toppled Thursday on a report CVS won't add the company's new HIV prevention drug, Yeztugo, to its commercial plans for now.

The Gilead HIV prevention shot , called Yevtugo, is highly effective, but its list price is $28, 218 a year in the U.S.

The Mount Gilead cross country boys picked up a team title Tuesday at the Upper Sandusky Icebreaker Invitational. The team scored 27 points to top the 14-team field. Columbus Grove was second with 48.

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

At a Television Critics Association panel on Jan 14., show creator Bruce Miller revealed that the writers foresaw Trump's ...

Interius is working on a more efficient way to deliver CAR-T therapy to patients. Unlock Digital Access for unlimited access to Inquirer.com and The Inquirer App, plus 5 articles per month to gift to ...

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could potentially widen access to CAR-T treatment.

The Handmaid's Tale got people talking right from the start. The show began in 2017 and threw us into Gilead, a scary place where women lose their rights and their names.

Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access.